Heidelberg Pharma and Huadong get NMPA nod for HDP-101 China trial
Heidelberg Pharma and Huadong Medicine received NMPA approval for the HDP-101 clinical trial in China, according to TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.